• Users Online: 208
  • Print this page
  • Email this page
Year : 2011  |  Volume : 5  |  Issue : 1  |  Page : 6-8

C5b-9 inhibitor (eculizumab) for antibody-mediated rejection in renal transplantation

1 Transplant Unit; Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, West Midlands, UK
2 Transplant Unit, University Hospitals Coventry and Warwickshire, Coventry, West Midlands, United Kingdom
3 Histocompatibility Laboratory, NHS Blood and Transplant, Birmingham, West Midlands, United Kingdom

Correspondence Address:
Rizwan Hamer
Renal unit University hospitals Coventry and Warwickshire CV2 2DX
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Get Permissions

Get Permissions

Increasingly successful protocols enabling HLA antibody incompatible renal transplantation have resulted in a rise in the incidence of antibody mediated rejection. There are limited options to treat this feared complication. Eculizumab, a potent inhibitor of the complement cascade, has recently been suggested as a possible addition to treatment of AMR. We report the use of eculizumab in three very high risk transplant recipients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal